210 related articles for article (PubMed ID: 24651411)
41. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
42. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
Bedaiwy MA; Abou-Setta AM; Desai N; Hurd W; Starks D; El-Nashar SA; Al-Inany HG; Falcone T
Fertil Steril; 2011 Mar; 95(3):906-14.e1-4. PubMed ID: 21145541
[TBL] [Abstract][Full Text] [Related]
43. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
44. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Llarena NC; Valentine LN; Liu X; Falcone T
J Assist Reprod Genet; 2018 Apr; 35(4):571-581. PubMed ID: 29470701
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
46. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
47. THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage.
Xiong J; Xue L; Li Y; Tang W; Chen D; Zhang J; Dai J; Zhou S; Lu Z; Wu M; Wang S
Eur J Endocrinol; 2021 May; 184(5):R177-R192. PubMed ID: 33630753
[TBL] [Abstract][Full Text] [Related]
48. The effect of cancer treatment on female fertility and strategies for preserving fertility.
Maltaris T; Seufert R; Fischl F; Schaffrath M; Pollow K; Koelbl H; Dittrich R
Eur J Obstet Gynecol Reprod Biol; 2007 Feb; 130(2):148-55. PubMed ID: 16979280
[TBL] [Abstract][Full Text] [Related]
49. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
50. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
51. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
52. Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin‑releasing hormone agonist.
Ma N; Chen G; Chen J; Cui M; Yin Y; Liao Q; Tang M; Feng X; Li X; Zhang S; Ma D; Chen G; Li K; Ai J
Oncol Rep; 2020 Nov; 44(5):1917-1928. PubMed ID: 33000247
[TBL] [Abstract][Full Text] [Related]
53. Use of hormonal protection for chemotherapy-induced gonadotoxicity.
Kim SS; Lee JR; Jee BC; Suh CS; Kim SH; Ting A; Petroff B
Clin Obstet Gynecol; 2010 Dec; 53(4):740-52. PubMed ID: 21048441
[TBL] [Abstract][Full Text] [Related]
54. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
[TBL] [Abstract][Full Text] [Related]
55. Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity.
Cho HW; Lee S; Min KJ; Hong JH; Song JY; Lee JK; Lee NW; Kim T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096794
[TBL] [Abstract][Full Text] [Related]
56. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Lambertini M; Cinquini M; Moschetti I; Peccatori FA; Anserini P; Valenzano Menada M; Tomirotti M; Del Mastro L
Eur J Cancer; 2017 Jan; 71():25-33. PubMed ID: 27940355
[TBL] [Abstract][Full Text] [Related]
57. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
58. Fertility protection: a novel approach using pretreatment with mesenchymal stem cell exosomes to prevent chemotherapy-induced ovarian damage in a mouse model.
Park HS; Seok J; Cetin E; Ghasroldasht MM; Liakath Ali F; Mohammed H; Alkelani H; Al-Hendy A
Am J Obstet Gynecol; 2024 Jul; 231(1):111.e1-111.e18. PubMed ID: 38378099
[TBL] [Abstract][Full Text] [Related]
59. The need to reduce gonadotoxicity! fertility reserve after chemotherapy for gynaecological cancer.
Caretto M; Simoncini T
Gynecol Endocrinol; 2021 Jun; 37(6):481-482. PubMed ID: 34008472
[No Abstract] [Full Text] [Related]
60. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
Zhang Y; Xiao Z; Wang Y; Luo S; Li X; Li S
PLoS One; 2013; 8(11):e80444. PubMed ID: 24312222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
